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mprovement of Heart Failure
fter Renal Transplantation
he Complex Maze of
ardio-Renal Interaction*
ector O. Ventura, MD, FACC,
andeep R. Mehra, MD, FACC
ew Orleans, Louisiana
“Learn to see, learn to hear, learn to feel and know by practice
alone you can become expert. Medicine is learned at the bedside
and not in the classroom.”
Sir William Osler (1)
ffering an insightful proposition, Osler correctly surmised
he importance of observation in the practice of medicine.
espite rapid medical advances in the last century, obser-
ation and reasoning remain integral guiding principles for
he practice of medicine. In this issue of the Journal, Wali et
l. (2) report an observational study of 103 patients with
ymptomatic systolic heart failure (HF) accompanying end-
tage kidney disease that underwent renal transplantation.
ontrary to prevailing assumptions of a nihilistic attitude
oward such patients, these investigators noted that HF
ymptoms and ventricular function improved in the vast
ajority of individuals, an effect notably achieved with a low
erioperative morbidity and mortality. Thus, this study
ispels two widely prevalent myths. First, most clinicians
ecry such patients as too high-risk to undergo kidney
ransplantation and second, that the HF is unlikely to
mprove and will necessarily be responsible for determining
he clinical fate after renal transplantation.
See page 1051
Nearly two centuries ago, Richard Bright (3) associated
idney and cardiovascular disease when he wrote “the
bvious structural changes in the heart [in patients with
hrunken kidneys] have consisted chiefly of hypertrophy
ith or without valve disease; and, what is most striking, out
f 52 cases of hypertrophy, no valvular disease whatsoever
ould be detected in 34.” More recently, clinical and
pidemiological studies demonstrated that cardiac disease is
frequent complication of advanced chronic kidney disease
nd the major cause of death in patients on renal replace-
ent therapy (1,4–7). Greaves and Sharpe (8) have shown
hat when compared to age-matched controls, dialysis-
ependent patients exhibit a 3.5-fold higher mortality.
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.t
From the Cardiomyopathy and Heart Transplantation Center, Ochsner Clinic
oundation, New Orleans, Louisiana.therosclerosis and HF are highly prevalent among patients
n renal replacement therapy, and the latter is an important
redictor of mortality (6–8). Stack et al. (9) have shown
hat the diagnosis of HF is recorded in 36% of patients
ndergoing dialysis therapy. In this analysis, the prevalence
f HF was the greatest among diabetics, and, in addition,
atients with HF had a higher prevalence of coronary artery
isease, cerebrovascular disease, and peripheral vascular
isease. Another study by Harnett et al. (7) demonstrated
hat independent risk factors for the development of HF in
atients with end-stage renal disease (ESRD) at the time of
nitiation on dialysis were systolic dysfunction, diabetes
ellitus, older age, and ischemic heart disease. Clinical
ymptoms of HF recurred in 56% of the patients during
ialysis, and this recurrence was linked with the presence of
schemia and systolic dysfunction, anemia, hypoalbumine-
ia, and hypertension during dialysis. More importantly,
he median survival of patients with HF at baseline was 36
onths compared to 62 months in patients without HF.
ecently, an analysis of the U.S. Renal Data System
ialysis Morbidity and Mortality Study (DMMS) Wave 2
emonstrated that HF is a major risk factor for hospitaliza-
ion and is associated with an 83% mortality at three years
fter a hospitalization for HF, similar to that following
yocardial infarction (80%) (10,11).
Renal transplantation has become standard of care for
atients with end-stage kidney disease because of the
mprovement in surgical techniques and the introduction of
ew and more powerful immunosuppressive agents (12).
olfe et al. (13) compared the outcomes of patients
waiting transplantation on dialysis with patients who
eceived kidney transplantation and demonstrated that after
hree to four years of follow-up, kidney transplantation
educed the risk of death overall by 68%. Moreover, kidney
ransplantation has been shown to be more cost-effective
han dialysis in the long term (14). Cardiovascular disease is
he leading cause of death in patients after kidney trans-
lantation; however, its rate is lower than patients on
ialysis. The cumulative incidence of coronary heart disease,
erebrovascular disease, and peripheral vascular disease 15
ears after renal transplantation has been estimated at 23%,
5%, and 15%, respectively (12).
Several studies have demonstrated regression of left
entricular hypertrophy and improvement of left ventricular
unction after successful kidney transplantation (15–17).
erreira et al. (15) prospectively studied 24 patients with
SRD in whom 24-h ambulatory blood pressure monitor-
ng and echocardiography were performed before and at 3,
, and 12 months after renal transplantation. The authors
emonstrated that at one year, patients with successful
idney transplantation had a significant decrease in blood
ressure, prevalence of left ventricular hypertrophy and left
entricular dilatation, and an improvement in left ventricu-
ar function. Moreover, another study (16) demonstrated
hat regression of left ventricular hypertrophy continues
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Editorial Comment April 5, 2005:1061–3eyond the first year after renal transplantation, persisting
nto the third and fourth years after transplantation. Failure
o regress was associated with older age, hypertension, high
ulse pressure in normal-sized hearts, and low pulse pres-
ure in dilated hearts. De Lima et al. (17) performed carotid
ltrasound and echocardiograms to evaluate the impact of
enal transplantation on the morphological and functional
haracteristics of the carotid arteries and heart in a group of
nd-stage renal failure patients without overt cardiovascular
isease. Twenty-two patients were evaluated 2 to 3 weeks
fter renal transplantation, and again 12 and 40 months
fter transplant. The authors demonstrated that successful
enal transplantation improves, but does not cause, complete
egression of the cardiovascular alterations of end-stage
idney disease. Only intima-media thickness was normal-
zed by transplantation, whereas left ventricular mass index
nd carotid and ventricular distensibility improved but
emained abnormal. Interestingly, they also conclude that,
n this group of patients, the duration of dialysis, weight
ain, high blood pressure, and high hematocrit adversely
ffect the rate of change of post-transplant cardiovascular
ypertrophy (17).
The hypothesis of an improvement in HF after kidney
ransplantation has been explored in small case series
15,18,19) and in a study utilizing data from the U.S. Renal
ata System (20). The latter included 11,369 patients with
SRD due to diabetes that were placed on a renal and
idney pancreas transplant list from July 1994 to June 1997.
n comparison to patients maintained on dialysis, those who
nderwent renal transplantation had a lower incidence of
F hospitalizations. Although clinically important, this
tudy did not include a systematic evaluation of left ventric-
lar function. On the contrary, the strengths of the inves-
igation by Wali et al. (2) lies in the large patient numbers,
omprehensive nature of preoperative evaluation, and sys-
ematic collection of data on left ventricular function by
ultiple gated acquisition (MUGA) scans. During
ollow-up after kidney transplant, MUGA scans were re-
eated at six months, one year, and at the last evaluation of
he follow-up period. Additionally, these investigators de-
ermined that a longer duration of dialysis in patients with
F was detrimental for improvement in ventricular func-
ion after renal transplantation. Unfortunately, the current
tudy only reports on left ventricular ejection fraction and
oes not detail other cardiac structural or volumetric param-
ters to definitively determine whether these favorable
hanges were truly accompanied by remodeling of the
entricle. This is important because shifts in ejection frac-
ion can occur simply in response to hemodynamic alter-
tions in preload. Nevertheless, the clinical implications of
he study lend credence to the notion that renal transplan-
ation can be performed safely in patients with advanced
tages of HF due to left ventricular dysfunction.
The mechanisms by which renal transplantation normal-
zes ventricular function remain a matter of speculation and
ere not evaluated in the Wali et al. (2) study. It isncreasingly recognized that the heart and kidney rely
losely upon each other for physiological health. Some have
ubbed aberrations in this close knit circuit to represent the
cardio-renal syndrome” (21). Even subclinical alterations in
enal function possess prognostic implications in patients
ith ventricular dysfunction (22,23). Conversely, the uremic
nvironment characterized by metabolic aberrations has
een shown to be deleterious to cardiac structure and
unction (24). Thus, studies have linked the development of
econdary parathyroidism and anemia as important corre-
ates of functional cardiac decline in patients with end-stage
idney disease (25,26). Similarly, the inflammatory milieu
hat accompanies uremia is also thought to be a pathophys-
ological candidate linked to cardiac dysfunction (27). In-
eed, case reports exist wherein parathyroidectomy is asso-
iated with recovery from ventricular failure in patients on
enal replacement therapy (28). Furthermore, the therapeu-
ic use of erythropoietin in HF with accompanying renal
nsufficiency has been demonstrated to improve ventricular
unction (29). Thus, it is tempting to speculate that the
mprovement of renal function after kidney transplantation
nd consequent resurrection of metabolic abnormalities
ight be responsible for the resolution of HF, even beyond
he hemodynamic effects of blood pressure and volume
ontrol. It is interesting that Wali et al. (2) noted trends in
mprovement of parathyroid hormone levels in those who
enefited compared to increases in this hormone in the
ohort that showed no improvement in ventricular function.
uch work is needed to better understand the reasons
nderlying the observed benefits on HF after renal trans-
lantation. The importance of insightful observations such
s the one reported herein is depicted in the sayings of
illiam Osler. He wrote: “There is no more difficult art to
cquire than the art of observation, and for some men it is
uite as difficult to record an observation in brief and plain
anguage” (1).
eprint requests and correspondence: Dr. Hector O. Ventura,
chsner Clinic Foundation, 1514 Jefferson Highway, New Or-
eans, Louisiana 70121. E-mail: Hventura@ochsner.org.
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